Eli Lilly Analyst Ratings
UBS Maintains Buy on Eli Lilly, Lowers Price Target to $1050
Morgan Stanley Adjusts Price Target on Eli Lilly to $1,133 From $1,124
Goldman Sachs Adjusts Price Target on Eli Lilly to $883 From $888
UBS Adjusts Price Target on Eli Lilly to $1,050 From $1,100, Maintains Buy Rating
Wells Fargo Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $1,100
BofA Securities Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $1,000
TD Cowen Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $1,050
Eli Lilly & Co (LLY) Gets a Buy From TD Cowen
Research Alert: Lly Q1 Results: Top-line Beat, Bottom-line Miss, 2025 Sales Guidance Intact
Wells Fargo Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $1,100
Wells Fargo Keeps Their Buy Rating on Eli Lilly & Co (LLY)
J.P. Morgan Maintains Eli Lilly and Co(LLY.US) With Buy Rating
Goldman Sachs Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $888
Eli Lilly Analyst Ratings
HSBC Downgrades Eli Lilly and Co(LLY.US) to Sell Rating, Cuts Target Price to $700
BofA Securities Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Announces Target Price $1,000
Bernstein Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $1,100
A Quick Look at Today's Ratings for Eli Lilly and Co(LLY.US), With a Forecast Between $975 to $1,124
Cantor Fitzgerald Initiates Coverage On Eli Lilly With Overweight Rating, Announces Price Target of $975